



GlaxoSmithKline Consumer Nigeria Plc  
1 Industrial Avenue, Ilupeju  
RC 8726  
PMB 21218  
Ikeja, Lagos  
Tel: +234 (01) 2711000, (01) 3242900  
[www.gsk.com/ng](http://www.gsk.com/ng)

**Lagos | Nigeria January 18, 2024**

**GLAXOSMITHKLINE CONSUMER NIGERIA PLC – SCHEME OF ARRANGEMENT - RECEIPT OF COURT SANCTION**

Following the Court Ordered Meeting held on December 5, 2023 - at which the shareholders of GlaxoSmithKline Consumer Nigeria Plc (“GSK Consumer Nigeria” or “GSK” or “the Company”) approved the proposed Scheme of Arrangement (“the Scheme”) - GSK Consumer Nigeria hereby notifies Nigerian Exchange Limited (“NGX”), our esteemed shareholders, and other stakeholders that the Company has now received Securities and Exchange Commission’s Formal Approval of the Scheme. The order of the Federal High Court sanctioning the Scheme of Arrangement has also been obtained.

An application for the delisting of the Company’s shares from the NGX will be submitted imminently.

Frederick Ichekwai  
**Company Secretary**

Tel: +234 (01) 2918000.Email: [Customer\\_ch\\_nigeria@gsk.com](mailto:Customer_ch_nigeria@gsk.com)

**Directors:** Mr. Edmund Onuzo, Chairman; Mr. Kunle Oyelana, Managing Director; Mr. Bosco Kirugi (Kenyan), Finance Director; Mrs. Oludewa Edodo-Thorpe; Ms. Amina Salihu; Mr. James West (British); Mr. Somer Tayyareci (British)